Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

The Path from Genome-based Research to Population Health: Development of an International Public Health Genomics Network Tables

This website is archived for historical purposes and is no longer being maintained or updated.

arrow  back to report

TABLE 1: HuGE* reviews, 1999–2002
Topic Reference no.
Gene variants associated with a high risk of disease
Medium chain acyl-CoA* dehydrogenase (MCAD) deficiency
16
Sickle hemoglobin (HbS) allele and sickle cell disease
17
NF1 gene and neurofibromatosis type 1
18
FMR1 and the fragile X syndrome
19
Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer
20
Common complex disorders
N-Acetyltransferase polymorphisms and colorectal cancer
26
Glutathione S-transferase polymorphisms and colorectal cancer
27
GSTM1, GSTT1, and risk of squamous cell carcinoma of the head and neck
29
Glutathione S-transferase polymorphisms and risk of ovarian cancer
30
Pooled analysis and meta-analysis of GSTM1 and bladder cancer
32
NAD(P)H*:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease
86
5,10-Methylenetetrahydrofolate reductase (MTHFR) gene variants and congenital anomalies
25
5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk
33
Molecular epidemiology of vitamin D receptor gene variants
28
Apolipoprotein E polymorphism and cardiovascular disease
31
HLA-DQ and type 1 diabetes mellitus
23
HFE gene and hereditary hemochromatosis
24
{delta} -Aminolevulinic acid dehydratase (ALAD) genotype and lead toxicity
87
GJB2 (connexin 26) variants and nonsyndromic sensorineural hearing loss
88
Androgen receptor CAG repeats and prostate cancer
89

* HuGE, Human Genome Epidemiology; acyl-CoA, acyl coenzyme A; NAD(P)H, nicotinamide adenine dinucleotide phosphate (reduced form).

arrow  back to report


TABLE 2: Proposed criteria for prioritizing HuGE* review topics
Content
Public health significance of the disease (in terms of morbidity and mortality)
Availability of effective interventions for genes modulating, or thought to modulate, an exposure
Effect on pathways involved in pathogenesis of multiple diseases of public health significance (e.g., methylation, DNA repair)
Relevance to common disease with evidence of gene-environment or gene-gene interactions
High potential population attributable risk, on the basis of at least two studies

* HuGE, Human Genome Epidemiology.

arrow  back to report


TABLE 3: Formats of HuGE* review†
Format Content
Full review
Information on gene(s), variants of gene(s) (defined, effect on function if known, and variation in genotype frequencies), disease(s), associations with disease(s), interactions, laboratory tests, population testing, other potential public health applications (e.g., setting permissible exposure thresholds), conclusions and recommendations for research,‡ references, Internet sites
Gene-disease association review
Similar to above, except that no information on the variation in genotype frequencies presented
Minireview
This is appropriate when the epidemiologic aspects of specific gene(s) have already been reviewed for HuGENet™,* but the associations between the gene and a different disease are being reviewed. In the section on gene variants, a summary (with reference) of the points covered in the full review(s) relating to this gene should be presented
Prevalence review
Information on gene(s), variants of gene(s) (definition and variation in genotype frequency), laboratory tests, conclusions and recommendations for research, references, Internet sites

* HuGE, Human Genome Epidemiology; HuGE Net, Human Genome Epidemiology Network.
† Detailed instructions are available at https://www.cdc.gov/genomics/hugenet/participate.htm.
‡ This was not requested explicitly in the previous guidelines (15).

arrow  back to report

TOP